Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Official Title

An Open-label, Multi-centre Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments

Summary:

The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.

Trial Description

Primary Outcome:

• Frequency and nature of AE and SAE by subject
• Number of subjects with PDR001 dose interruption and/or reduction

• Number of subjects receiving PDR001
• Subject's exposure duration

View this trial on ClinicalTrials.gov